- Home
- AVIR vs MGNX Comparison
AVIR vs MGNX Comparison
Compare AVIR & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- MGNX
- Stock Information
- Founded
- AVIR 2012
- MGNX 2000
- Country
- AVIR United States
- MGNX United States
- Employees
- AVIR N/A
- MGNX N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- MGNX Health Care
- Exchange
- AVIR Nasdaq
- MGNX Nasdaq
- Market Cap
- AVIR 276.9M
- MGNX 257.3M
- IPO Year
- AVIR 2020
- MGNX 2013
- Fundamental
- Price
- AVIR $3.25
- MGNX $3.21
- Analyst Decision
- AVIR Hold
- MGNX Buy
- Analyst Count
- AVIR 1
- MGNX 11
- Target Price
- AVIR $6.88
- MGNX $8.57
- AVG Volume (30 Days)
- AVIR 178.7K
- MGNX 753.5K
- Earning Date
- AVIR 11-07-2024
- MGNX 11-05-2024
- Dividend Yield
- AVIR N/A
- MGNX N/A
- EPS Growth
- AVIR N/A
- MGNX N/A
- EPS
- AVIR N/A
- MGNX N/A
- Revenue
- AVIR N/A
- MGNX $141,329,000.00
- Revenue This Year
- AVIR N/A
- MGNX $119.63
- Revenue Next Year
- AVIR N/A
- MGNX N/A
- P/E Ratio
- AVIR N/A
- MGNX N/A
- Revenue Growth
- AVIR N/A
- MGNX 16.68
- 52 Week Low
- AVIR $2.81
- MGNX $2.95
- 52 Week High
- AVIR $4.60
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- AVIR 44.03
- MGNX 36.82
- Support Level
- AVIR $3.10
- MGNX $3.61
- Resistance Level
- AVIR $3.48
- MGNX $5.10
- Average True Range (ATR)
- AVIR 0.13
- MGNX 0.36
- MACD
- AVIR -0.01
- MGNX -0.10
- Stochastic Oscillator
- AVIR 29.52
- MGNX 2.58
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).